Evidence map›Paper›PMID 40695675›Full record

ArticleEBioMedicine2025

Exposure to per- and poly-fluoroalkyl substances in association to later occurrence of type 2 diabetes and metabolic pathway dysregulation in a multiethnic US population.

Vishal Midya, Meizhen Yao, Elena Colicino, Dinesh Barupal, Xiangping Lin, Chris Gennings, Leda Chatzi, Veronica Wendy Setiawan, Ruth J F Loos, Ryan W Walker and 2 more

Abstract read
In one paragraph

Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Vishal MidyaDepartment of Environmental Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: vishal.midya@mssm.edu.
Meizhen YaoDepartment of Environmental Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Elena ColicinoDepartment of Environmental Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Dinesh BarupalDepartment of Environmental Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Xiangping LinDepartment of Genetics, Stanford University School of Medicine, Palo Alto, CA, USA.
Chris GenningsDepartment of Environmental Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Leda ChatziDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Veronica Wendy SetiawanDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Ruth J F LoosThe Charles Bronfman Institutes for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Ryan W WalkerDepartment of Environmental Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Douglas I WalkerGangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Damaskini ValviDepartment of Environmental Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Funding

Translational Research Support CoreP30ES007048 · NIEHS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROB S MCCONNELL · 1996 to 2026
$46.4M
The Mount Sinai Transdisciplinary Center on Early Environmental ExposuresP30ES023515 · NIEHS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Chris Gennings · 2014 to 2026
$21.3M
Perfluoroalkyl substances and incident type 2 diabetes in a US population: A metabolome-genome investigationR01ES033688 · NIEHS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Damaskini Valvi · 2022 to 2026
$3.2M
Perfluoroalkyl substances and non-alcoholic fatty liver disease in children: Leveraging magnetic resonance imaging to unravel potential mechanisms and exposure mixture effectsR21ES035148 · NIEHS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI OULHOTE, YOUSSEF, VALVI, DAMASKINI · 2023 to 2023
$479k
NIEHS NIH HHS P30 ES007048NIEHS NIH HHS P30 ES023515NIEHS NIH HHS R01 ES033688NIEHS NIH HHS R21 ES035148
6 · The paper itself

Abstract

backgroundGrowing evidence suggests that exposure to per- and polyfluoroalkyl substances (PFAS) are linked to an increased risk of type 2 diabetes (T2D); however, the effect of PFAS mixtures and underlying mechanisms are not well understood. We examined the associations between exposure to PFAS mixture with later T2D diagnosis and underlying metabolic dysregulations.

methodsWe conducted a nested case-control study within BioMe, an electronic health record-linked biobank of >65,000 patients seeking primary care at Mount Sinai Hospital, New York, since 2007. After excluding prevalent T2D cases at baseline, we selected 180 incident T2D cases (33% African Americans, 33% Hispanics, 33% Whites) and 180 age, sex, and ancestry-matched T2D-free controls. In prediagnostic plasma collected at baseline (∼6 years before diagnosis), we quantified seven PFAS and untargeted metabolomic profiles. We used Weighted Quantile Sum regression to evaluate the PFAS mixture association with the odds for incident T2D. We analysed the associations between ∼650 annotated metabolites and the PFAS mixture or T2D odds using Hierarchical Bayesian Weighted Quantile Sum and logistic regression, respectively, adjusting for matching factors and other confounders. Pathway enrichment analyses were performed using Mummichog.

findingsEach tertile increase in the PFAS mixture was associated with higher odds of incident T2D (OR [95% CI] = 1.31 [1.01, 1.70]), with Perfluorooctane Sulfonate (PFOS) having the highest contribution to this association. Metabolites associated with both the PFAS mixture and T2D odds were 5-hydroxytryptophan, glucoheptulose, and sulfolithocholylglycine; the associations with sulfolithocholylglycine survived multiple testing corrections. Pathways associated with both the PFAS mixture and T2D were glutamate metabolism, arginine and proline metabolism, and drug metabolism-cytochrome p450.

interpretationExposure to PFAS mixtures may be associated with increased odds for T2D in multiethnic populations via dysregulations in amino acid and drug metabolism. Larger investigations in multiethnic populations are required to elucidate the potential PFAS contribution to metabolic alterations and T2D risk.

fundingNational Institutes of Health (R01ES033688, P30ES023515, R21ES035148, R35ES030435, R01ES032242, R01ES034521, R01ES029944, R01ES030364, U01HG013288, R21ES037112 and P30ES007048).

Indexed as

Diabetes Mellitus, Type 2Environmental ExposureEnvironmental PollutantsFluorocarbonsMetabolic Networks and PathwaysAdultAgedBiomarkersCase-Control StudiesFemaleHumansMaleMetabolomicsMiddle AgedUnited StatesBiomarkersEnvironmental PollutantsFluorocarbonsExposomicsExposure mixtureMetabolomicsPer-and polyfluoroalkyl substancesType 2 diabetes

Identifiers

PMID40695675
PMCPMC12368339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.